Extended-release formulation of levetiracetam — same SV2A binding mechanism, once-daily dosing improves adherence. Same pharmacology as IR levetiracetam.
Half-Life & Elimination Curve (PO: 7h)
Plasma (PO)t½ Decay (7h)
0×t½0h100%(15.2 mg/L)
1×t½7h50%(7.62 mg/L)
2×t½14h25%(3.81 mg/L)
3×t½21h12.5%(1.91 mg/L)
4×t½28h6.3%(0.953 mg/L)
5×t½35h3.1%(0.476 mg/L)
Elimination t½7h (PO)
Rate Constant (ke)0.099 h⁻¹
Time to Peak (Tmax)5.52h
Est. Peak (Cmax)15.2 mg/L
Clearance (CL)3.76 L/h
97% Washout (5×t½)35h
Dosing Guidelines
Oral (PO): Typical 1000 mg (Range: 500–3000 mg)
Pharmacokinetic Parameters
Oral (PO): Bioavailability (F): 100% · Volume of Distribution (Vd): 38 L · Absorption (ka): 0.3 h⁻¹ (t½ka ≈ 2.31h) [PMID 19264451]